Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Imbruvica
Pharma
On 2nd glance, analyst reverses rosy view on IRA cuts
The rosy view of the 2026 Medicare drug price cuts under the Inflation Reduction Act may have missed an important point, one analyst group argues.
Fraiser Kansteiner
Aug 19, 2024 5:21pm
AZ makes case for Calquence in another blood cancer type
Jun 17, 2024 11:25am
AZ clinches early Calquence win in untreated MCL
May 2, 2024 10:24am
As Imbruvica fails, Brukinsa wins FDA nod in follicular lymphoma
Mar 7, 2024 4:08pm
An Imbruvica combo regimen could have a new future in MCL
Dec 12, 2023 12:33pm
Lilly's Jaypirca blazes CLL trail with FDA approval
Dec 4, 2023 4:11am
